A recent study showed that pretreatment with α-GalCer could prompt a subset of iNKT cells to produce large amounts of interleukin-10 (IL-10) and to acquire regulatory cellular characteristics, subsequently impairing anti-tumor immune responses and alleviating the pathogenesis of experimental autoimmune encephalomyelitis. This evidence concerns the gene IL10 and experimental autoimmune encephalomyelitis.